These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28231624)

  • 1. Targets and Mechanisms in Prevention of Parkinson's Disease through Immunomodulatory Treatments.
    von Euler Chelpin M; Vorup-Jensen T
    Scand J Immunol; 2017 May; 85(5):321-330. PubMed ID: 28231624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
    Tsai SJ
    Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Effects of Bee Venom on Immunological and Neurological Diseases.
    Hwang DS; Kim SK; Bae H
    Toxins (Basel); 2015 Jun; 7(7):2413-21. PubMed ID: 26131770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation in Parkinson's disease.
    Tufekci KU; Meuwissen R; Genc S; Genc K
    Adv Protein Chem Struct Biol; 2012; 88():69-132. PubMed ID: 22814707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The key role of T cells in Parkinson's disease pathogenesis and therapy.
    Baird JK; Bourdette D; Meshul CK; Quinn JF
    Parkinsonism Relat Disord; 2019 Mar; 60():25-31. PubMed ID: 30404763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory vaccines against autoimmune diseases.
    Sela M
    Rejuvenation Res; 2006; 9(1):126-33. PubMed ID: 16608409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer cells of Parkinson's disease patients are set up for activation: a possible role for innate immunity in the pathogenesis of this disease.
    Mihara T; Nakashima M; Kuroiwa A; Akitake Y; Ono K; Hosokawa M; Yamada T; Takahashi M
    Parkinsonism Relat Disord; 2008; 14(1):46-51. PubMed ID: 17702627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
    Duda PW; Schmied MC; Cook SL; Krieger JI; Hafler DA
    J Clin Invest; 2000 Apr; 105(7):967-76. PubMed ID: 10749576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roquinimex-mediated protection effect on the development of chronic graft-versus-host disease in mice is associated with induction of Th1 cytokine production and inhibition of proinflammatory cytokine production.
    Xiao ZY; Zhou WX; Zhang YX; Cheng JP; He JF; Yang RF; Yun LH
    Life Sci; 2007 Oct; 81(19-20):1403-10. PubMed ID: 17950363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Th17 cells: a promising therapeutic target for Parkinson's disease?
    Prots I; Winner B
    Expert Opin Ther Targets; 2019 Apr; 23(4):309-314. PubMed ID: 30871383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial correction of the TH2/TH1 imbalance in neonatal murine responses to vaccine antigens through selective adjuvant effects.
    Barrios C; Brandt C; Berney M; Lambert PH; Siegrist CA
    Eur J Immunol; 1996 Nov; 26(11):2666-70. PubMed ID: 8921953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H1521, a novel derivative of 4-hydroxyquinoline-3-carboxamide, suppresses the development of lupus in mice by inducing Th1 cytokine profile in T cells.
    Xiao ZY; Chen SH; Zhou WX; Zhang YX; Cheng JP; Yang RF
    Int Immunopharmacol; 2011 Apr; 11(4):435-43. PubMed ID: 21195814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Th1 or Th2: how an appropriate T helper response can be made.
    Bergmann C; Van Hemmen JL; Segel LA
    Bull Math Biol; 2001 May; 63(3):405-30. PubMed ID: 11374299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies.
    Rocha NP; de Miranda AS; Teixeira AL
    Biomed Res Int; 2015; 2015():628192. PubMed ID: 26295044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell therapy for Parkinson's disease: Functional role of the host immune response on survival and differentiation of dopaminergic neuroblasts.
    Wenker SD; Leal MC; Farías MI; Zeng X; Pitossi FJ
    Brain Res; 2016 May; 1638(Pt A):15-29. PubMed ID: 26239914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
    Sarkar S; Raymick J; Imam S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroinflammation in Parkinson's disease and its potential as therapeutic target.
    Wang Q; Liu Y; Zhou J
    Transl Neurodegener; 2015; 4():19. PubMed ID: 26464797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platycodin D2 is a potential less hemolytic saponin adjuvant eliciting Th1 and Th2 immune responses.
    Xie Y; Deng W; Sun H; Li D
    Int Immunopharmacol; 2008 Aug; 8(8):1143-50. PubMed ID: 18550019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCG priming of dendritic cells enhances T regulatory and Th1 function and suppresses allergen-induced Th2 function in vitro and in vivo.
    Ahrens B; Gruber C; Rha RD; Freund T; Quarcoo D; Awagyan A; Hutloff A; Dittrich AM; Wahn U; Hamelmann E
    Int Arch Allergy Immunol; 2009; 150(3):210-20. PubMed ID: 19494518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugs.
    Bassani TB; Vital MA; Rauh LK
    Arq Neuropsiquiatr; 2015 Jul; 73(7):616-23. PubMed ID: 26200058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.